The companies will combine their respective technologies to create a platform for discovering and developing drugs for certain genetic diseases.
The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
Centogene will help Aldeyra identify patients with Sjögren-Larsson Syndrome, a rare genetic disease for which Aldeyra is developing a treatment.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
Under a new agreement, Centogene will integrate its CentoMD database of phenotype/genotype variants of rare diseases into the Qiagen bioinformatics platform.
Centogene said it will use the funds to accelerate growth and expansion in the areas of genetic testing, pharmaceutical collaborations, and big-data solutions.
The partners will work to offer panel-based genetic characterization for a US-based cohort.
The company has installed Illumina's HiSeq X sequencing platform and expects to sequence 20,000 genomes by the end of next year.
The two companies plan to join their respective technologies in order to help clinicians better interpret genetic variant data.
The privately-held German firm also plans to offer genetic tumor profiling and noninvasive prenatal testing.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.